Related Experiment Video
Updated: Jul 18, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Plasma S100beta and NSE levels and progression in multiple sclerosis
Marcus Koch1, Jop Mostert, Dorothea Heersema
1Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. m.w.koch@neuro.umcg.nl
Journal of the Neurological Sciences
|December 26, 2006
Summary
Plasma neuron-specific enolase (NSE) levels may indicate multiple sclerosis (MS) progression. Lower NSE levels were associated with increased disability and a progressive disease course in MS patients over five years.
Area of Science:
- Neuroscience
- Biomarkers
- Neurology
Background:
- Plasma S100beta and neuron-specific enolase (NSE) are glial and neuronal markers, respectively, elevated in central nervous system damage.
- Multiple Sclerosis (MS) is a chronic neurological disease characterized by central nervous system damage.
Purpose of the Study:
- To investigate the relationship between plasma S100beta and NSE levels and disease progression in multiple sclerosis (MS).
- To assess if these biomarkers correlate with disability and disease course in different MS subtypes.
Main Methods:
- Plasma S100beta and NSE levels were measured in 64 patients across relapsing remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) cohorts.
- Patients were evaluated over a five-year follow-up period for disease progression and disability using the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Status (MSSS).
Main Results:
- Plasma NSE levels were significantly lower in patients experiencing clinically relevant worsening of EDSS scores and those with a progressive disease course.
- A significant negative correlation was observed between plasma NSE levels and both EDSS and MSSS scores at baseline and after five years.
- No significant differences in plasma S100beta levels were found between patient groups or in relation to disease progression.
Conclusions:
- Plasma NSE levels show an inverse relationship with disease progression and disability in multiple sclerosis.
- NSE may serve as a potential biomarker for monitoring disease activity and progression in MS patients.
- S100beta did not demonstrate a significant association with MS progression in this study cohort.
